Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
NCT ID: NCT01244750
Last Updated: 2022-06-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1494 participants
OBSERVATIONAL
2010-12-02
2020-01-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States
NCT03045120
Study Conducted Among Patients With CML
NCT05476562
Mid-to Long-Term Outcomes in Chronic Myeloid Leukemia (CML) Patients With Complete Cytogenetic Response After Imatinib as First Line Therapy
NCT00896129
Study of Treatment Free Remission in Patients With Chronic Myeloid Leukemia in Chronic Phase
NCT05926128
Efficacy, Safety and Long-term Prognosis of Imatinib in Patients Newly Diagnosed With Chronic Myelogenous Leukemia (Chronic Phase)
NCT00237120
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
First line TKI treatment: Imatinib
Diagnosed CML patients who receive first line TKI treatment: Imatinib
No interventions assigned to this group
First line TKI treatment: Nilotinib
Diagnosed CML patients who receive first line TKI treatment: Nilotinib
No interventions assigned to this group
First line TKI treatment: Dasatinib
Diagnosed CML patients who receive first line TKI treatment: Dasatinib
No interventions assigned to this group
Imatinib treated patients
Imatinib treated patients if their study index date is between January 2, 2008 and September 30, 2010
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 18 years or older at time of of CP-CML diagnosis
a) Imatinib Cohorts
* Patients who started their first-line Imatinib treatment between January 2, 2008 and September 30, 2010.Patients fitting this criterion are defined as retrospective Imatinib patients
* Patients who started their first-line Imatinib treatment on or after October 1, 2010
b) Dasatinib Cohort
* Patients who started their first-line Dasatinib treatment after the drug was approved in this indication
c) Nilotinib Cohort
* Patients who started their first-line Nilotinib treatment after the drug was approved in this indication
* Patients are also eligible when they have already switched to a subsequent therapy (TKI or other) at the time of enrollment, as long as their first-line and subsequent CML treatment information is available at site for data entry into the study Electronic Case Report Form (eCRF)
* Receiving treatment at medical practice (eg. community-based, office-based, hospital-based, academic setting, oncology center)
Exclusion Criteria
Discontinuation Criteria:
* Enrolled patients who join an interventional trial which may influence the management of their CML disease will be excluded at the time of entry into the interventional trial
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ICON Clinical Research
INDUSTRY
Bristol-Myers Squibb
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Northwest Alabama Cancer Center
Muscle Shoals, Alabama, United States
Arizona Oncology Associates, PC - HAL
Phoenix, Arizona, United States
Arizona Oncology Associates, PC - NAHOA
Sedona, Arizona, United States
Arizona Oncology Associates, PC - HOPE
Tucson, Arizona, United States
Genesis Cancer Center
Hot Springs, Arkansas, United States
NEA Baptist Clinic
Jonesboro, Arkansas, United States
Little Rock Hematology Oncology Associates
Little Rock, Arkansas, United States
Pacific Cancer Medical Center, Inc
Anaheim, California, United States
Southwest Cancer Care Medical Group
Escondido, California, United States
Wilshire Oncology Medical Group, Inc
Glendora, California, United States
University of Southern California
Los Angeles, California, United States
St. Joseph's Hospital
Orange, California, United States
PMK Medical Group, Inc. DBA Ventura
Oxnard, California, United States
Stockton Hematology Oncology
Stockton, California, United States
Tahoe Forest Health System Cancer Center
Truckee, California, United States
Rocky Mountain Cancer Centers
Boulder, Colorado, United States
Medical Oncology and Blood Disorders, LLP
Manchester, Connecticut, United States
Stamford Hospital
Stamford, Connecticut, United States
Washington Hospital Center, Washington Cancer Institute
Washington D.C., District of Columbia, United States
George Washington University
Washington D.C., District of Columbia, United States
Hematology And Medical Oncology Of Southern Palm Beach County
Boynton Beach, Florida, United States
Broward Oncology Associates
Fort Lauderdale, Florida, United States
Palm Springs Research Institute
Hialeah, Florida, United States
Baptist Cancer Institute
Jacksonville, Florida, United States
University Of Florida
Jacksonville, Florida, United States
Watson Clinic
Lakeland, Florida, United States
Central Florida Health Alliance
Leesburg, Florida, United States
Baptist Cancer Center
Miami, Florida, United States
Florida Cancer Specialists
New Port Richey, Florida, United States
Cancer Centers of Florida
Orlando, Florida, United States
Lake County Oncology and Hematology
Tavares, Florida, United States
Space Coast Cancer Center
Titusville, Florida, United States
Peachtree Hematology-Oncology
Atlanta, Georgia, United States
Emory University
Atlanta, Georgia, United States
Northwest Georgia Oncology Centers, PC
Marietta, Georgia, United States
Georgia Cancer Specialist
Sandy Springs, Georgia, United States
Lewis Hall Singeltary Oncology Center
Thomasville, Georgia, United States
OnCare
Honolulu, Hawaii, United States
Straub Clinical & Hospital
Honolulu, Hawaii, United States
Kaiser Permanente Honolulu
Honolulu, Hawaii, United States
Mahafzah Medical Center
Evergreen Park, Illinois, United States
Delnor Community Hospital
Geneva, Illinois, United States
Mid-Illinois Hem/Onc Asoc
Normal, Illinois, United States
North Chicago VA Medical Center
North Chicago, Illinois, United States
Southern Illinois School of Medicine
Springfield, Illinois, United States
Carle Cancer Center
Urbana, Illinois, United States
Central DuPage Hospital
Winfield, Illinois, United States
Saint John's Cancer Center
Anderson, Indiana, United States
Indiana Blood and Marrow Transplantation
Indianapolis, Indiana, United States
Investigative Clinical Research of Indiana
Indianapolis, Indiana, United States
Horizon Oncology Research, Inc
Lafayette, Indiana, United States
Cancer Care Center, Inc. PC
New Albany, Indiana, United States
N. Iowa Mercy Cancer Center
Mason City, Iowa, United States
Hutchinson Clinic
Hutchinson, Kansas, United States
Cotton O'Neil Cancer Center
Topeka, Kansas, United States
Cancer Center of Kansas
Wichita, Kansas, United States
Central Baptist Hospital
Lexington, Kentucky, United States
University of Louisville Hospital - Brown Cancer Center
Louisville, Kentucky, United States
Consultants In Blood Disorders
Saint Matthews, Kentucky, United States
Ochsner Clinic Foundation
New Orleans, Louisiana, United States
Willis-Knighton Cancer System
Shreveport, Louisiana, United States
Maryland Oncology Hematology Pa
Columbia, Maryland, United States
Frederick Memorial Hospital
Frederick, Maryland, United States
Sturdy Hematology & Oncology Associates
Attleboro, Massachusetts, United States
Boston VA Healthcare System
Boston, Massachusetts, United States
South Coast Health System
Fall River, Massachusetts, United States
Commonwealth Hematology-Oncology, P.C.
Quincy, Massachusetts, United States
UMass Medical Center
Worcester, Massachusetts, United States
Cancer & Hematology Centers of Western Michigan
Grand Rapids, Michigan, United States
West Michigan Cancer Center
Kalamazoo, Michigan, United States
Michigan State University
Lansing, Michigan, United States
North Mississippi Hematology & Oncology
Tupelo, Mississippi, United States
St John's Clinic for Cancer and Hematology
Springfield, Missouri, United States
Billings Clinic
Billings, Montana, United States
Omaha VAMC
Omaha, Nebraska, United States
Portsmouth Regional Hospital
Portsmouth, New Hampshire, United States
Bms Clinical Research Center
Does Not Exist, New Jersey, United States
Hackensack University Medical Center
Hackensack, New Jersey, United States
Hematology-Oncology Associates of Northern NJ, PA
Morristown, New Jersey, United States
Southern Oncology Hematology
Vineland, New Jersey, United States
Broome Oncology
Johnson City, New York, United States
Advanced Oncology
New York, New York, United States
St. Lukes Roosevelt Medical Center
New York, New York, United States
Vassar Brothers Medical Center
Poughkeepsie, New York, United States
Stony Brook University Hospital
Stony Brook, New York, United States
Montefiore Medical Center / AECOM
The Bronx, New York, United States
Alamance Regional Cancer Center
Burlington, North Carolina, United States
Waverly Hematology Oncology
Cary, North Carolina, United States
Duke University Medical Center
Durham, North Carolina, United States
Gaston Hematology Oncology
Gastonia, North Carolina, United States
East Carolina University
Greenville, North Carolina, United States
Akron General Medical Center
Akron, Ohio, United States
Gabrail Cancer Center
Canton, Ohio, United States
Signal Point Clinical Research Center, LLC
Middletown, Ohio, United States
Medical Center of Newark
Newark, Ohio, United States
Cancer Care Associates
Tulsa, Oklahoma, United States
Oregon Health & Science University
Portland, Oregon, United States
Hematology/Oncology Salem LLP
Salem, Oregon, United States
Lehigh Valley Hospital
Allentown, Pennsylvania, United States
St. Luke's Hospital and Health Network
Bethlehem, Pennsylvania, United States
Medical Oncology Associates of Wyoming Valley, PC
Kingston, Pennsylvania, United States
Lancaster General Health
Lancaster, Pennsylvania, United States
Veterans Research Foundation of Pittsburgh
Pittsburgh, Pennsylvania, United States
Berks Hematology-Oncology
West Reading, Pennsylvania, United States
Geisinger Health System
Wilkes-Barre, Pennsylvania, United States
Cancer Care Association Of York
York, Pennsylvania, United States
Hematology and Oncology Associates of RI
Cranston, Rhode Island, United States
The Cancer Center at Memorial Hospital
Pawtucket, Rhode Island, United States
Charleston Cancer Center
Charleston, South Carolina, United States
Avera Research Institute
Sioux Falls, South Dakota, United States
Prairie Lakes Healthcare System, Inc
Watertown, South Dakota, United States
Tennessee Cancer Specialists
Knoxville, Tennessee, United States
University of Tennessee Medical Center
Knoxville, Tennessee, United States
Texas Oncology
Amarillo, Texas, United States
Texas Oncology - Arlington South
Arlington, Texas, United States
Texas Oncology-Austin North
Austin, Texas, United States
Julie & Ben Rogers Cancer Institute
Beaumont, Texas, United States
Texas Oncology-Medical City Dallas
Dallas, Texas, United States
Texas Oncology-Dallas Presbyterian Hospital
Dallas, Texas, United States
Texas Oncology-Methodist Charlton Cancer Center
Dallas, Texas, United States
MD Anderson Cancer Center
Houston, Texas, United States
Michael DeBakey VA Medical Center
Houston, Texas, United States
Texas Oncology
Lewisville, Texas, United States
Texas Oncology-McAllen South Second
McAllen, Texas, United States
Texas Oncology
Mesquite, Texas, United States
Texas Oncology-Midland Allison Cancer Center
Midland, Texas, United States
Texas Oncology-Odessa West Texas Cancer Center
Odessa, Texas, United States
Texas Oncology
Paris, Texas, United States
North Texas Regional Cancer Center
Plano, Texas, United States
Cancer Care Centers of South Texas
San Antonio, Texas, United States
Texas Oncology
Waco, Texas, United States
Danville Hematology & Oncology
Danville, Virginia, United States
Hematology Oncology Associates of Fredricksburg
Fredericksburg, Virginia, United States
Peninsula Cancer Institute
Newport News, Virginia, United States
Blue Ridge Cancer Care
Roanoke, Virginia, United States
Swedish Cancer Institute-Eastside Hematology/Oncology
Bellevue, Washington, United States
Providence Cancer Center at Sacred Heart Medical Center
Spokane, Washington, United States
Wenatchee Valley Medical Center
Wenatchee, Washington, United States
Yakima Valley Memorial Hospital/North Star Lodge
Yakima, Washington, United States
Charleston Area Medical Center
Charleston, West Virginia, United States
City Hospital - West Virginia University Hospital East
Martinsburg, West Virginia, United States
Wheeling Hospital
Wheeling, West Virginia, United States
Aspirus Regional Cancer Center
Wausau, Wisconsin, United States
Local Institution
Blois, , France
Local Institution
Bordeaux, , France
Local Institution
Chalon/Saone Cedex, , France
Local Institution
Chambéry, , France
Local Institution
Le Mans, , France
Local Institution
Pierre-Bénite, , France
Local Institution
Pringy, , France
Local Institution
Amberg, , Germany
Local Institution
Aschaffenburg, , Germany
Local Institution
Baden-Baden, , Germany
Local Institution
Bamberg, , Germany
Local Institution
Berlin, , Germany
Local Institution
Berlin, , Germany
Local Institution
Bonn, , Germany
Local Institution
Bottrop, , Germany
Local Institution
Coburg, , Germany
Local Institution
Cologne, , Germany
Local Institution
Cologne, , Germany
Local Institution
Darmstadt, , Germany
Local Institution
Essen, , Germany
Local Institution
Frankfurt am Main, , Germany
Local Institution
Frankurt Am Main, , Germany
Local Institution
Greifswald, , Germany
Local Institution
Hamm, , Germany
Local Institution
Hof, , Germany
Local Institution
Idar-Oberstein, , Germany
Local Institution
Kaiserslautern, , Germany
Local Institution
Kassel, , Germany
Local Institution
Koblenz, , Germany
Local Institution
Landshut, , Germany
Local Institution
Lebach, , Germany
Local Institution
Leipzig, , Germany
Local Institution
Mülheim A. D. Ruhr, , Germany
Local Institution
Offenbach, , Germany
Local Institution
Potsdam, , Germany
Local Institution
Rostock, , Germany
Local Institution
Rötha, , Germany
Local Institution
Singen, , Germany
Local Institution
Soest, , Germany
Local Institution
Ulm, , Germany
Local Institution
Velbert, , Germany
Local Institution
Weiden, , Germany
Local Institution
Würzburg, , Germany
Local Institution
Bari, , Italy
Local Institution
Brescia, , Italy
Local Institution
Brindisi, , Italy
Local Institution
Catania, , Italy
Local Institution
Florence, , Italy
Local Institution
Milan, , Italy
Local Institution
Milan, , Italy
Local Institution
Modena, , Italy
Local Institution
Monza, , Italy
Local Institution
Pavia, , Italy
Local Institution
Perugia, , Italy
Local Institution
Pesaro, , Italy
Local Institution
Rionero in Vulture, , Italy
Local Institution
Roma, , Italy
Local Institution
Rome, , Italy
Local Institution
Rome, , Italy
Local Institution
Siena, , Italy
Local Institution
Terni, , Italy
Local Institution
Udine, , Italy
Local Institution
Hoofddorp, , Netherlands
Puerto Rico Hematology Oncology Group
Bayamón, , Puerto Rico
Local Institution
Saint Petersburg, , Russia
Local Institution
Santiago de Compostela-A Coruña, Spain, Spain
Local Institution
A Coruña, , Spain
Local Institution
Oviedo - Asturias, , Spain
Local Institution
Pamplona, , Spain
Local Institution
Salamanca, , Spain
Local Insitution
Toledo, , Spain
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Hehlmann R, Cortes JE, Zyczynski T, Gambacorti-Passerini C, Goldberg SL, Mauro MJ, Michallet M, Simonsson B, Williams LA, Gajavelli S, DeGutis I, Sen GP, Paquette RL. Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY. Am J Hematol. 2019 Jan;94(1):46-54. doi: 10.1002/ajh.25306. Epub 2018 Oct 31.
Related Links
Access external resources that provide additional context or updates about the study.
FDA Safety Alerts and Recalls
BMS Clinical Trial Information
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CA180-330
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.